The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells

Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer

(2013) Xian Li et al.   CANCER LETTERS

Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5′-phosphatase interaction with c-Abl

(2013) D. Mokhtari et al.   DIABETOLOGIA

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

(2013) Sampurna Chatterjee et al.   JOURNAL OF CLINICAL INVESTIGATION

VEGF-A/VEGFR-2 Signaling Plays an Important Role for the Motility of Pancreas Cancer Cells

(2011) Yosuke Doi et al.   ANNALS OF SURGICAL ONCOLOGY

Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications

(2011) Brahma N. Singh et al.   BIOCHEMICAL PHARMACOLOGY

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

(2011) K. J. Gotink et al.   CLINICAL CANCER RESEARCH

Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene

(2011) Jing Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

(2011) Hiromichi Ebi et al.   JOURNAL OF CLINICAL INVESTIGATION

Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability

(2011) Jun Ge et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Sunitinib for the treatment of metastatic renal cell carcinoma

(2010) Stéphane Oudard et al.   CANCER TREATMENT REVIEWS

Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer

(2010) David J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922

(2010) W. B. Nagengast et al.   JOURNAL OF NUCLEAR MEDICINE

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

(2010) H. J. Hammers et al.   MOLECULAR CANCER THERAPEUTICS

Green tea (−)-epigallocatechin gallate inhibits insulin stimulation of 3T3-L1 preadipocyte mitogenesis via the 67-kDa laminin receptor pathway

(2009) Hui-Chen Ku et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

(2009) Kristy J. Gotink et al.   ANGIOGENESIS

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

(2009) S Novello et al.   BRITISH JOURNAL OF CANCER

Synergistic Growth Inhibition of Squamous Cell Carcinoma of the Head and Neck by Erlotinib and Epigallocatechin-3-Gallate: The Role of p53-Dependent Inhibition of Nuclear Factor- B

(2009) A. R. M. R. Amin et al.   Cancer Prevention Research

The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer Cells

(2009) S. A. Milligan et al.   CLINICAL CANCER RESEARCH

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

(2009) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

(2009) A. C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE